ScoreWhy is Aspira Pathlab & Diagnostics Ltd ?
1
Weak Long Term Fundamental Strength with a 16.95% CAGR growth in Operating Profits over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.80
- The company has been able to generate a Return on Capital Employed (avg) of 9.26% signifying low profitability per unit of total capital (equity and debt)
2
The company has declared Positive results for the last 3 consecutive quarters
- NET SALES(HY) At Rs 11.59 cr has Grown at 70.94 %
- PAT(HY) Higher at Rs 1.37 cr
3
Stock is technically in a Mildly Bullish range
- The stocks MACD and KST technical factors are also Bullish
4
With ROE of 7.7, it has a Attractive valuation with a 6.1 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 110.72%, its profits have risen by 135% ; the PEG ratio of the company is 0.5
5
Majority shareholders : Non Institution
6
Market Beating Performance
- Even though the market (BSE 500) has generated negative returns of -0.99% in the last 1 year, the stock has been able to generate 110.72% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Aspira Pathlab should be less than 10%
- Overall Portfolio exposure to Hospital & Healthcare Services should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Hospital & Healthcare Services)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Aspira Pathlab for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Aspira Pathlab
110.72%
1.76
63.08%
SENSEX
0.45%
0.03
14.48%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
26.38%
EBIT Growth (5y)
16.95%
EBIT to Interest (avg)
0.80
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.75
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-17.97%
ROE (avg)
14.16%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
68
Industry P/E
55
Price to Book Value
6.11
EV to EBIT
67.94
EV to EBITDA
28.55
EV to Capital Employed
6.08
EV to Sales
3.39
PEG Ratio
0.50
Dividend Yield
NA
ROCE (Latest)
-2.42%
ROE (Latest)
7.65%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend18What is working for the Company
NET SALES(HY)
At Rs 11.59 cr has Grown at 70.94 %
PAT(HY)
Higher at Rs 1.37 cr
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Aspira Pathlab
Profit After Tax (PAT) - Half Yearly
At Rs 1.37 cr has Grown at 194.48 %
Year on Year (YoY)MOJO Watch
PAT trend is very positive
PAT (Rs Cr)
Net Sales - Half Yearly
At Rs 11.59 cr has Grown at 70.94 %
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Profit After Tax (PAT) - Half Yearly
Higher at Rs 1.37 cr
than preceding 12 month period ended Dec 2024 of Rs -1.97 crMOJO Watch
In the half year the company has already crossed PAT of the previous twelve months
PAT (Rs Cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
